Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: lymphoma

Lymphoma Risk in RA Patients Remains Steady

Kurt Ullman  |  September 17, 2017

Patients with a diagnosis of rheumatoid arthritis (RA) experience on average double the risk of developing malignant lymphoma when compared with the general population. With the major changes in RA treatment taking place over the past decade, has there been a reduction in the risk of lymphoma in this population? Researchers from the Karolinska Institute…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:ACR Journal ReviewAmerican College of Rheumatology (ACR)ClinicalDisease-modifying antirheumatic drugs (DMARDs)lymphomamalignancyMedicationoutcomepatient careregistryResearchRheumatoid arthritisriskSwedish Rheumatology QualityTreatmentTumor Necrosis Factor–Alpha Inhibitor

Innate Immune Response Predicts Development of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome

Lara C. Pullen, PhD  |  June 12, 2017

The P2X7 receptor inflammasome axis may have a role in the pathogenesis of Sjögren’s syndrome and non-Hodgkin’s lymphoma. According to new research, patients with Sjögren’s syndrome who developed non-Hodgkin’s lymphoma had an increased expression of the P2X7R-inflammasome axis and the glandular expression of IL-18, suggesting a possible novel biomarker…

Filed under:ConditionsOther Rheumatic ConditionsSjögren’s Disease Tagged with:Cancernon-Hodgkin’s lymphomaP2X7 receptor inflammasomeSjogren's

FDA Approvals: Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  May 31, 2025

Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:belimumabFDA approvalLupus nephritis supplementvoclosporin

Trials Find Potential Treatments for SLE, Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  May 31, 2025

In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:dapirolizumab pegolLupus nephritis supplementobinutuzumab

B Cell-Depleting Therapy in SLE & Lupus Nephritis

Katie Robinson  |  May 31, 2025

“B cells are central orchestraters of autoimmune disease by contributing to autoantibody production, antigen presentation and cytokine production,” says Georg Schett, MD, head of the Department of Medicine 3 (Rheumatology and Immunology) of the Friedrich-Alexander University Erlangen-Nürnberg, Germany. “B cells can be inhibited by monoclonal antibodies and chimeric antigen receptor (CAR) expressing cells.” Dr. Schett…

Filed under:ConditionsResearch ReviewsResearch RheumSystemic Lupus Erythematosus Tagged with:B cell depleting therapyB cell depletionCAR-T cell therapyCD19 CAR-T cell treatmentLupus nephritis supplement

Lupus Nephritis: A Brief Review

Keri Losavio  |  May 15, 2025

Among patients with sys­temic lupus erythematosus (SLE), lupus nephritis is one of the more common health problems and a leading cause of mortality. In adults with SLE, as many as five of 10 will develop kidney disease. In children with lupus, eight of 10 will develop kidney disease.1 Lupus nephritis appears to be more prevalent…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lupus nephritis

mRNA CAR T Cell Therapy Receives FDA’s Rare Pediatric Designation to Treat Juvenile Dermatomyositis

Michele B. Kaufman, PharmD, BCGP  |  January 30, 2025

FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesMyositis Tagged with:chimeric antigen receptor T (CAR-T) cellsFDAjuvenile dermatomyositisU.S. Food and Drug Administration (FDA)

Strong Argument: Recent Developments in Myositis Diagnosis & Care

Jason Liebowitz, MD, FACR  |  January 15, 2025

Lisa Christopher-Stine, MD, MPH, discussed the latest findings on myositis and its subtypes, including insights into antibodies linked to cancer and treatments for these patients.

Filed under:ConditionsEULAR/OtherMeeting ReportsMyositis Tagged with:Antisynthetase SyndromeCancerdermatomyositisDiagnosispatient carepolymyositis

The Great Imitator: Updates on Sarcoidosis

Jason Liebowitz, MD, FACR  |  January 15, 2025

Michelle Sharp, MD, MHS, shared insights into the complexities of sarcoidosis, describing how she evaluates, diagnoses and treats patients.

Filed under:ConditionsEULAR/OtherMeeting ReportsOther Rheumatic Conditions Tagged with:neurosarcoidosispatient carepulmonary sarcoidosisSarcoidosis

Skin Matters: The Intersection of Dermatology & Rheumatology

Jason Liebowitz, MD, FACR  |  January 1, 2025

Jun Kang, MD, addressed the intersection of dermatology and rheumatology, describing the nuance necessary to accurately evaluate skin manifestations and differentiate multiple conditions.

Filed under:ConditionsEULAR/OtherMeeting ReportsMyositisSystemic Lupus Erythematosus Tagged with:cutaneous lupus erythematosus (CLE)Dermatologydermatomyositisneutrophilic dermatosesskinskin disease

  • 1
  • 2
  • 3
  • …
  • 17
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences